Seattle Genetics Reports Second Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/24/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Americold to wind down Ahold Delhaize facilities, take $305M charge
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Did Google and Tesla just break AI trade’s bull case?
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- Matador Resources to acquire Paloma Permian for $1.275B
Seattle Genetics (SGEN) Tops Q2 EPS by 51c, Revenues Beat; Offers FY20 Revenue Guidance
July 30, 2020 4:16 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q2 EPS of ($0.12), $0.51 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $278 million versus the consensus estimate of $256.43 million.
PRODUCT SALES SUMMARY
ADCETRIS: Continued growth with net sales in the U.S. and Canada of $167.5 million in the second quarter of 2020, an increase of five percent over the second quarter of 2019.PADCEV: U.S. net sales in the... More